BORIANI, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 81.441
EU - Europa 27.244
AS - Asia 14.677
SA - Sud America 3.541
OC - Oceania 324
AF - Africa 245
Continente sconosciuto - Info sul continente non disponibili 52
Totale 127.524
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 80.685
GB - Regno Unito 10.551
SG - Singapore 4.986
IT - Italia 4.878
CN - Cina 4.008
BR - Brasile 3.161
DE - Germania 2.739
SE - Svezia 2.625
HK - Hong Kong 2.305
TR - Turchia 1.920
UA - Ucraina 1.764
RU - Federazione Russa 1.531
BG - Bulgaria 861
FI - Finlandia 538
FR - Francia 489
ID - Indonesia 453
BZ - Belize 400
AU - Australia 309
IE - Irlanda 218
NL - Olanda 208
CA - Canada 190
AT - Austria 147
IN - India 135
PL - Polonia 131
ES - Italia 116
AR - Argentina 91
JP - Giappone 91
MX - Messico 85
IQ - Iraq 82
LT - Lituania 79
BE - Belgio 72
EC - Ecuador 64
UZ - Uzbekistan 63
CO - Colombia 57
PK - Pakistan 56
MY - Malesia 54
ZA - Sudafrica 52
BD - Bangladesh 46
MA - Marocco 46
VN - Vietnam 46
VE - Venezuela 44
CH - Svizzera 42
CL - Cile 41
RO - Romania 39
IR - Iran 38
GE - Georgia 37
AZ - Azerbaigian 36
EU - Europa 36
IL - Israele 36
TN - Tunisia 32
GR - Grecia 30
PE - Perù 29
EG - Egitto 27
RS - Serbia 27
KE - Kenya 26
CZ - Repubblica Ceca 25
NP - Nepal 25
JO - Giordania 24
TW - Taiwan 24
AE - Emirati Arabi Uniti 23
PH - Filippine 22
PY - Paraguay 20
JM - Giamaica 19
KG - Kirghizistan 19
KR - Corea 19
PT - Portogallo 19
DO - Repubblica Dominicana 18
KZ - Kazakistan 18
TH - Thailandia 18
UY - Uruguay 18
HU - Ungheria 17
BO - Bolivia 16
DZ - Algeria 15
NZ - Nuova Zelanda 15
DK - Danimarca 14
PS - Palestinian Territory 13
SN - Senegal 12
AL - Albania 11
CU - Cuba 11
SA - Arabia Saudita 11
PA - Panama 10
SK - Slovacchia (Repubblica Slovacca) 10
A2 - ???statistics.table.value.countryCode.A2??? 9
LB - Libano 9
NO - Norvegia 9
CR - Costa Rica 8
LV - Lettonia 8
MD - Moldavia 8
AM - Armenia 7
BY - Bielorussia 7
KH - Cambogia 7
QA - Qatar 7
BA - Bosnia-Erzegovina 6
EE - Estonia 6
LA - Repubblica Popolare Democratica del Laos 6
LK - Sri Lanka 6
NG - Nigeria 6
SI - Slovenia 6
XK - ???statistics.table.value.countryCode.XK??? 6
CY - Cipro 5
Totale 127.444
Salva come PNG Salva come JPEG
Città #
Fairfield 12.851
Woodbridge 7.524
Southend 7.258
Santa Clara 7.051
Houston 5.830
Ashburn 5.786
Seattle 4.963
Cambridge 4.149
Chandler 4.145
Wilmington 4.073
Jacksonville 3.636
Singapore 3.032
Ann Arbor 2.815
London 2.527
Dearborn 2.335
Hong Kong 2.251
Modena 1.463
Nyköping 1.463
Beijing 1.325
San Diego 1.246
Izmir 1.216
New York 1.109
Princeton 893
Sofia 856
San Jose 847
Eugene 729
Moscow 499
Jakarta 440
Belize City 400
Council Bluffs 350
Helsinki 343
Dallas 326
Milan 318
Falls Church 256
Bologna 228
Rome 218
Boardman 217
São Paulo 202
Dublin 194
Chicago 189
Fremont 187
Shanghai 180
Saint Louis 169
Perth 168
Norwalk 163
Las Vegas 139
Albuquerque 134
Nuremberg 133
Hefei 128
Redwood City 120
Kunming 116
Atlanta 111
Nanjing 110
Guangzhou 105
Kilburn 100
Columbus 94
Rio de Janeiro 93
Munich 90
Los Angeles 89
Belo Horizonte 85
Toronto 81
Grafing 75
Lappeenranta 75
Jinan 69
Naples 68
Amsterdam 63
Florence 62
Chiswick 61
Sydney 58
Tashkent 58
Brasília 57
Brussels 56
Curitiba 54
Vienna 54
Prescot 51
Nanchang 49
Parma 49
Hounslow 48
Turin 47
Saint Petersburg 45
Sergii 43
Fuzhou 42
Porto Alegre 42
Wuhan 41
Tokyo 40
Zhengzhou 40
Reggio Emilia 39
Des Moines 36
Philadelphia 36
San Giuliano Milanese 35
Baghdad 34
Baku 34
Shenyang 34
Campinas 32
Ottawa 32
Ribeirão Preto 32
Bremen 31
Frankfurt am Main 31
Paris 31
San Francisco 31
Totale 99.963
Salva come PNG Salva come JPEG
Nome #
Long-Term Implications of Atrial Fibrillation in Patients With Degenerative Mitral Regurgitation 584
La sindrome da pacemaker. 407
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC (Eur Heart J (2021) 42 (373–498) DOI: 10.1093/eurheartj/ehaa612) 396
Atrial Fibrillation in the Setting of Acute Pneumonia: Not a Secondary Arrhythmia 380
Linee guida AIAC all'impianto di pacemaker, dispositivi per la resincronizzazione cardiaca, defibrillatori automatici e loop recorder. Update 2011. 354
Registro Italiano Pacemaker e Defibrillatori: Bollettino Periodico 2016 Associazione Italiana di Aritmologia e Cardiostimolazione 323
Screening for atrial fibrillation: A Report of the AF-SCREEN International Collaboration 320
The future of continuing medical education: the roles of medical professional societies and the health care industry: Position paper prepared with contributions from the European Society of Cardiology Committees for Advocacy, Education and Industry Relations, Endorsed by the Board of the European Society of Cardiology 287
Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial 280
Prevalence and clinical significance of left bundle branch block according to classical or strict definition criteria in permanent pacemaker patients 280
Guía de práctica clínica de la ESC 2013 sobre estimulación cardiaca y terapia de resincronización cardiaca 271
2018 EHRA expert consensus statement on lead extraction: Recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: Endorsed by APHRS/HRS/LAHRS 268
Clinically guided pacemaker choice and setting: pacemaker expert programming study 253
Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol 246
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA) 241
Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality 239
Implantable cardioverter-defibrillator–computed respiratory disturbance index accurately identifies severe sleep apnea: The DASAP-HF study 239
Role of the tricuspid regurgitation after mitraclip and transcatheter aortic valve implantation: a systematic review and meta-analysis 237
Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation 237
108th ENMC International Workshop, 3rd Workshop of the MYO-CLUSTER project: EUROMEN, 7th International Emery-Dreifuss Muscular Dystrophy (EDMD) Workshop, 13-15 September 2002, Naarden, The Netherlands. 236
'Real-world' management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: The EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry 236
The 2018 European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Executive summary 235
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report 230
Health economics and the European Heart Rhythm Association. 228
P wave dispersion and short-term vs. late atrial fibrillation recurrences after cardioversion 227
Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter-defibrillator therapies and hospitalizations 226
Home care for heart failure: can caregiver education prevent hospital admissions? A randomized trial in primary care 224
QRS interval time-related changes and prognosis in heart failure 223
Letter by Gasparini and Boriani Regarding Article, "Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation: Results From the Resynchronization for Ambulatory Heart Failure Trial (RAFT)" 221
Cardiac device therapy in patients with left ventricular dysfunction and heart failure: ‘real-world’ data on long-term outcomes (mortality, hospitalizations, days alive and out of hospital) 221
2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing 221
The increased risk of stroke/transient ischemic attack in women with a cardiac implantable electronic device is not associated with a higher atrial fibrillation burden 219
12-year Temporal Trend in Referral Pattern and Test Results of Stress Echocardiography in a Tertiary Care Referral Center with Moderate Volume Activities and Cath-lab Facility 217
Prediction of cardiac resynchronization therapy response: value of calibrated integrated backscatter imaging. 216
Emery-Dreifuss Muscular Dystrophy-Associated Mutant Forms of Lamin A Recruit the Stress Responsive Protein Ankrd2 into the Nucleus, Affecting the Cellular Response to Oxidative Stress 216
Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden 216
Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry 215
Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF 215
Cardiac involvement in systemic sclerosis: identification of high-risk patient profiles in different patterns of clinical presentation 215
QRS pattern and improvement in right and left ventricular function after cardiac resynchronization therapy: a radionuclide study 213
'Real-world' atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase 212
Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples 212
Risk stratification of cardiovascular and heart failure hospitalizations using integrated device diagnostics in patients with a cardiac resynchronization therapy defibrillator 212
The wearable cardioverter-defibrillator: Current technology and evolving indications 212
Elevated TGF β2 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes 211
EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation 211
New classification of geometric patterns considering left ventricular volume in patients with chronic aortic valve regurgitation: Prevalence and association with adverse cardiovascular outcomes 211
Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation 209
Beta-blocker treatment guided by head-up tilt test in neurally mediated syncope 209
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy 208
Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry 208
Remote Monitoring of Patients with an Implanted Device and Patients' Outcomes: The Potential for "Win-Win" Dynamics. 207
Cardiolaminopathies from bench to bedside: challenges in clinical decision-making with focus on arrhythmia-related outcomes 207
Cardiac resynchronization therapy: is systole all that matters? 206
Inappropriate shock for myopotential over-sensing in a patient with subcutaneous ICD 206
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 206
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy 204
The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) Randomized Controlled Trial: Phase 1 Results on Dynamics of Early Intervention With Remote Monitoring 204
Decrease in patient radiation exposure by a tantalum filter during electrophysiological procedures. 202
Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. 202
Combined use of morphology discrimination, sudden onset, and stability as discriminating algorithms in single chamber cardioverter defibrillators 202
New-generation atrial antitachycardia pacing (Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: Results from the MINERVA randomized multicenter international trial 202
Validation of a simple risk stratification tool for patients implanted with Cardiac Resynchronization Therapy: The VALID-CRT risk score 202
Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary 202
Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action 202
Asymptomatic lone atrial fibrillation - how can we detect the arrhythmia? 201
Randomized comparison between Ramp and Burst+ atrial antitachycardia pacing therapies in patients suffering from sinus node disease and atrial fibrillation and implanted with a DDDRP device 201
Overweight and obesity in patients with atrial fibrillation: Sex differences in 1-year outcomes in the EORP-AF General Pilot Registry 201
The QRS interval in patients treated with resynchronization therapy: which value? 200
Management of Phrenic Stimulation in CRT Patients over the Long Term: Still an Unmet Need ? 200
European Society of Cardiology-Proposed Diagnostic Echocardiographic Algorithm in Elective Patients with Clinical Suspicion of Infective Endocarditis: Diagnostic Yield and Prognostic Implications in Clinical Practice 200
Cardiac resynchronization therapy in the real world: need to upgrade outcome research 200
Heart failure after myocardial revascularization: Risk markers 199
Cardiac resynchronization therapy: effects on left and right ventricular ejection fraction during exercise. 199
Health care cost analysis of enhanced pacing modalities in bradycardia patients: Portuguese case study on the results of the MINERVA trial 199
Cardiac resynchronization therapy in the real world: need to focus on implant rates, patient selection, co-morbidities, type of devices, and complications 199
Implantable dual-chamber defibrillator for the selective treatment of spontaneous atrial and ventricular arrhythmias: arrhythmia incidence and device performance. 199
'Pill-in-the-pocket' treatment for recent-onset atrial fibrillation [4] 199
Far-field R wave oversensing in dual-chamber pacemakers designed for atrial arrhythmia management: effect of pacing site and lead tip to ring distance 198
Rhythm discrimination by rate branch and QRS morphology in dual chamber implantable cardioverter defibrillators 198
A randomized double-blind comparison of biventricular versus left ventricular stimulation for cardiac resynchronization therapy: the Biventricular versus Left Univentricular Pacing with ICD Back-up in Heart Failure Patients (B-LEFT HF) trial. 198
Effect of high-pass filtering on ECG signal on the analysis of patients prone to atrial fibrillation 197
Atrial evoked response integral for automatic capture verification in atrial pacing 197
Meta-analysis of clinical outcomes of electrical cardioversion and catheter ablation in patients with atrial fibrillation and chronic kidney disease 197
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: A joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) 197
Cost Effectiveness of Treatments for Stroke Prevention in Atrial Fibrillation: Focus on the Novel Oral Anticoagulants 197
Cardiac resynchronization by pacing: an electrical treatment of heart failure 196
Reducing unnecessary right ventricular pacing with the managed ventricular pacing mode in patients with sinus node disease and AV block. 196
Ventricular fibrillation during sleep in an adolescent with hypertrophic cardiomyopathy: the difficulty of risk stratification and the power of the cardioverter-defibrillator 196
Targeting the arrhythmogenic substrate in atrial fibrillation: focus on structural remodeling 195
Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy 195
Switching among Equivalents in Chronic Cardiovascular Therapies: 'Real World' Data from Italy 195
Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. 195
Cardiac tachyarrhythmias and patient values and preferences for their management: The European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) 195
Cardiac resynchronization and implantable cardioverter defibrillator therapy: Preliminary results from the InSync Implantable Cardioverter Defibrillator Italian Registry 195
Cardiac resynchronization therapy and electrical storm: results of the OBSERVational registry on long-term outcome of ICD patients (OBSERVO-ICD) 195
Extending survival by reducing sudden death with implantable cardioverter-defibrillators: a challenging clinical issue in non-ischaemic and ischaemic cardiomyopathies 195
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC) 195
P-wave characteristics after electrical external cardioversion: Predictive indexes of relapse 195
Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: Results of markov modelling in a european population 194
Totale 22.589
Salva come PNG Salva come JPEG
Categoria #
all - tutte 583.715
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 583.715
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206.250 0 0 0 0 0 0 0 0 3.021 1.172 1.531 526
2020/202122.437 1.993 841 2.000 2.486 2.603 1.348 2.848 2.882 1.051 2.005 1.309 1.071
2021/202215.465 664 1.848 1.677 712 427 1.286 887 786 1.655 1.369 2.411 1.743
2022/202311.536 1.660 974 714 826 1.469 1.536 259 1.187 1.758 206 597 350
2023/20249.853 393 632 435 803 2.283 1.440 447 1.696 223 253 327 921
2024/202524.074 1.151 386 730 1.788 4.911 5.157 3.774 2.151 4.026 0 0 0
Totale 130.652